Peter Schmid

24.3k total citations · 11 hit papers
207 papers, 11.0k citations indexed

About

Peter Schmid is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Peter Schmid has authored 207 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Oncology, 135 papers in Pulmonary and Respiratory Medicine and 61 papers in Cancer Research. Recurrent topics in Peter Schmid's work include Advanced Breast Cancer Therapies (111 papers), Cancer Immunotherapy and Biomarkers (78 papers) and Cancer Treatment and Pharmacology (59 papers). Peter Schmid is often cited by papers focused on Advanced Breast Cancer Therapies (111 papers), Cancer Immunotherapy and Biomarkers (78 papers) and Cancer Treatment and Pharmacology (59 papers). Peter Schmid collaborates with scholars based in United Kingdom, United States and Spain. Peter Schmid's co-authors include Sherene Loi, Hope S. Rugo, Hiroji Iwata, Eric P. Winer, Sylvia Adams, Carlos H. Barrios, Leisha A. Emens, Luciana Molinero, Véronique Dièras and Jane Yuet Ching Hui and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Peter Schmid

197 papers receiving 10.9k citations

Hit Papers

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negati... 2018 2026 2020 2023 2018 2019 2022 2018 2018 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
    2018 3.0k citations Peter Schmid, Sylvia Adams et al. New England Journal of Medicine profile →
  2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
    2019 846 citations Peter Schmid, Hope S. Rugo et al. The Lancet Oncology profile →
  3. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
    2022 594 citations Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine profile →
  4. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
    2018 567 citations Leisha A. Emens, Cristina Cruz et al. profile →
  5. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
    2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →
  6. Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
    2018 348 citations Tiffany A. Traina, Joyce O’Shaughnessy et al. Journal of Clinical Oncology profile →
  7. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
    2021 330 citations Eric P. Winer, Seock‐Ah Im et al. The Lancet Oncology profile →
  8. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
    2021 205 citations Leisha A. Emens, Luciana Molinero et al. JNCI Journal of the National Cancer Institute profile →
  9. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
    2021 192 citations Peter Schmid et al. profile →
  10. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
    2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →
  11. Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
    2025 16 citations Komal Jhaveri, Seock‐Ah Im et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Schmid United Kingdom 44 8.3k 3.5k 3.2k 2.6k 2.1k 207 11.0k
Luciana Molinero United States 37 6.6k 0.8× 2.2k 0.6× 2.1k 0.7× 3.4k 1.3× 1.6k 0.8× 102 9.2k
Leisha A. Emens United States 52 10.7k 1.3× 3.1k 0.9× 2.6k 0.8× 6.0k 2.3× 2.9k 1.3× 166 14.5k
Thomas Bachelot France 41 5.8k 0.7× 3.0k 0.9× 1.9k 0.6× 1.8k 0.7× 1.9k 0.9× 241 8.4k
Sara M. Tolaney United States 54 11.6k 1.4× 5.3k 1.5× 3.7k 1.2× 1.7k 0.7× 2.8k 1.3× 502 14.8k
Roberto Salgado Belgium 34 6.5k 0.8× 1.7k 0.5× 2.6k 0.8× 2.9k 1.1× 1.7k 0.8× 147 8.7k
Naiyer A. Rizvi United States 61 11.0k 1.3× 7.7k 2.2× 2.2k 0.7× 3.0k 1.2× 3.5k 1.6× 275 15.0k
Joohyuk Sohn South Korea 44 7.9k 1.0× 5.6k 1.6× 3.3k 1.0× 666 0.3× 1.8k 0.9× 303 10.9k
Roberto Hegg Brazil 25 6.6k 0.8× 2.3k 0.7× 2.4k 0.7× 1.3k 0.5× 1.5k 0.7× 87 8.3k
Binghe Xu China 41 6.1k 0.7× 2.8k 0.8× 3.0k 0.9× 808 0.3× 3.2k 1.5× 387 9.1k
Mark Ayers United States 33 5.2k 0.6× 1.9k 0.6× 2.7k 0.8× 1.6k 0.6× 2.5k 1.2× 56 7.8k

Countries citing papers authored by Peter Schmid

Since Specialization
Citations

This map shows the geographic impact of Peter Schmid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Schmid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Schmid more than expected).

Fields of papers citing papers by Peter Schmid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Schmid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Schmid. The network helps show where Peter Schmid may publish in the future.

Co-authorship network of co-authors of Peter Schmid

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Schmid. A scholar is included among the top collaborators of Peter Schmid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Schmid. Peter Schmid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Schmid, Peter, Haruhiko Miyata, Ilkka Miinalainen, et al.. (2024). Ccer1 is a spermatid-specific gene required for spermatogenesis and male fertility. The International Journal of Developmental Biology. 68(4). 251–262.
3.
4.
Pusztai, Lajos, Carsten Denkert, Joyce O’Shaughnessy, et al.. (2024). Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Annals of Oncology. 35(5). 429–436. 47 indexed citations breakdown →
5.
Cescon, David W., Peter Schmid, Hope S. Rugo, et al.. (2023). Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. JNCI Journal of the National Cancer Institute. 116(5). 717–727. 7 indexed citations
6.
Dent, Rebecca, David W. Cescon, Thomas Bachelot, et al.. (2023). TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncology. 19(35). 2349–2359. 29 indexed citations
7.
Marmé, Frederik, Hope S. Rugo, Sara M. Tolaney, et al.. (2023). 194P Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC). ESMO Open. 8(1). 101383–101383. 9 indexed citations
8.
Rudin, Charles M., Andrés Cervantes, Afshin Dowlati, et al.. (2023). Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. ESMO Open. 8(2). 101160–101160. 8 indexed citations
9.
Cortés, Javier, Hope S. Rugo, David W. Cescon, et al.. (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 387(3). 217–226. 594 indexed citations breakdown →
10.
Rugo, Hope S., Aditya Bardia, Sara M. Tolaney, et al.. (2020). TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer. Future Oncology. 16(12). 705–715. 89 indexed citations
11.
Huang, Min, Joyce O’Shaughnessy, Jing Zhao, et al.. (2020). Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Research. 80(24). 5427–5434. 89 indexed citations
12.
13.
Schmid, Peter, Hope S. Rugo, Sylvia Adams, et al.. (2019). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 21(1). 44–59. 846 indexed citations breakdown →
14.
Loi, Sherene, Peter Schmid, Gursel Aktan, Vassiliki Karantza, & Roberto Salgado. (2019). Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial. Annals of Oncology. 30. iii2–iii2. 17 indexed citations
15.
Winters, Zoë, Jonathan Horsnell, Karen T Elvers, et al.. (2018). Systematic review of the impact of breast‐conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open. 2(4). 162–174. 24 indexed citations
16.
Schmid, Peter, Yeon Hee Park, Eva Muñoz‐Couselo, et al.. (2017). Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. Journal of Clinical Oncology. 35(15_suppl). 556–556. 68 indexed citations
17.
Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2017). Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. Journal of Clinical Oncology. 35(15_suppl). 1088–1088. 55 indexed citations
18.
Schmid, Peter, Cristina Cruz, Fadi S. Braiteh, et al.. (2017). Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Research. 77(13_Supplement). 2986–2986. 92 indexed citations
19.
Nathan, Mark R. & Peter Schmid. (2017). A Review of Fulvestrant in Breast Cancer. Oncology and Therapy. 5(1). 17–29. 128 indexed citations
20.
Syed, Nelofer, Helen M. Coley, Jalid Sehouli, et al.. (2011). Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer. Cancer Research. 71(9). 3317–3327. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Luciana Molinero Breakdown of academic impact, for papers by Leisha A. Emens Breakdown of academic impact, for papers by Thomas Bachelot Breakdown of academic impact, for papers by Sara M. Tolaney Breakdown of academic impact, for papers by Roberto Salgado Breakdown of academic impact, for papers by Naiyer A. Rizvi Breakdown of academic impact, for papers by Joohyuk Sohn Breakdown of academic impact, for papers by Roberto Hegg Breakdown of academic impact, for papers by Binghe Xu Breakdown of academic impact, for papers by Mark Ayers
Rankless by CCL
2026